| Patent application number | Description | Published |
|---|
| 20090048444 | Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives - The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) | 02-19-2009 |
| 20090197871 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis. | 08-06-2009 |
| 20090203657 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, | 08-13-2009 |
| 20090203677 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics - The present invention relates to novel compounds of Formula (I) | 08-13-2009 |
| 20090239846 | Novel Compounds - Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 09-24-2009 |
| 20090275604 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 11-05-2009 |
| 20100093765 | NOVEL COMPOUNDS - Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 04-15-2010 |
| 20100093766 | NOVEL COMPOUNDS - Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 04-15-2010 |
